Mirion Technologies, Inc. MIR
We take great care to ensure that the data presented and summarized in this overview for Mirion Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIR
View all-
Goldman Sachs Group Inc New York, NY34.8MShares$375 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.3MShares$229 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.6MShares$222 Million0.14% of portfolio
-
Black Rock Inc. New York, NY15.6MShares$168 Million0.0% of portfolio
-
Swedbank Ab Stockholm, V710.8MShares$116 Million0.21% of portfolio
-
Janus Henderson Group PLC London, X09.4MShares$101 Million0.06% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL6.92MShares$74.6 Million0.51% of portfolio
-
Select Equity Group, L.P. New York, NY5.96MShares$64.2 Million0.25% of portfolio
-
P2 Capital Partners, LLC New York, NY5.52MShares$59.5 Million7.42% of portfolio
-
Dimensional Fund Advisors LP Austin, TX5.08MShares$54.7 Million0.02% of portfolio
Latest Institutional Activity in MIR
Top Purchases
Top Sells
About MIR
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, and Japan. It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.
Insider Transactions at MIR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 28
2024
|
Thomas D Logan Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
7,500
-100.0%
|
$75,000
$10.86 P/Share
|
May 28
2024
|
Thomas D Logan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
7,500
+50.0%
|
-
|
May 28
2024
|
Thomas D Logan Chief Executive Officer |
SELL
Conversion of derivative security
|
Indirect |
7,500
-0.29%
|
-
|
Apr 01
2024
|
Emmanuelle Lee Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,520
-6.05%
|
$71,720
$11.37 P/Share
|
Apr 01
2024
|
Brian Schopfer Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,834
-7.02%
|
$163,174
$11.37 P/Share
|
Apr 01
2024
|
Christopher A. Moore Chief Accounting Officer (PAO) |
SELL
Payment of exercise price or tax liability
|
Direct |
3,455
-8.69%
|
$38,005
$11.37 P/Share
|
Apr 01
2024
|
Alison Ulrich Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,859
-8.24%
|
$31,449
$11.37 P/Share
|
Apr 01
2024
|
Thomas D Logan Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
56,098
-6.91%
|
$617,078
$11.37 P/Share
|
Mar 28
2024
|
Lawrence D Kingsley Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,679
+4.23%
|
-
|
Mar 28
2024
|
Steven W. Etzel Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,898
+3.25%
|
-
|
Mar 28
2024
|
John W Kuo Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,898
+3.25%
|
-
|
Mar 28
2024
|
Kenneth Bockhorst Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,227
+3.84%
|
-
|
Mar 20
2024
|
Brian Schopfer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
90,910
-30.1%
|
$1,000,010
$11.0 P/Share
|
Mar 20
2024
|
Brian Schopfer Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
90,910
-12.27%
|
-
|
Mar 20
2024
|
Brian Schopfer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,910
+23.13%
|
-
|
Mar 01
2024
|
Emmanuelle Lee Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,060
+12.26%
|
-
|
Mar 01
2024
|
Alison Ulrich Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,040
+22.45%
|
-
|
Mar 01
2024
|
Brian Schopfer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,240
+22.2%
|
-
|
Mar 01
2024
|
Thomas D Logan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
156,626
+16.17%
|
-
|
Mar 01
2024
|
Christopher A. Moore Chief Accounting Officer (PAO) |
BUY
Grant, award, or other acquisition
|
Direct |
7,530
+15.93%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 489K shares |
---|
Sale (or disposition) back to the issuer | 90.9K shares |
---|---|
Payment of exercise price or tax liability | 145K shares |
Open market or private sale | 98.4K shares |
Conversion of derivative security | 7.5K shares |